       Document 0559
 DOCN  M9630559
 TI    Specific considerations for cost-effectiveness studies in AIDS.
 DT    9603
 AU    Bozzette SA; Medical Service, San Diego Veteran's Affairs Medical
       Center, CA; 92161, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 4:S23-7.
       Unique Identifier : AIDSLINE MED/96075586
 AB    HIV disease is an epidemic with unique features that make it a
       challenging topic for pharmacoeconomic analysis. Unlike many other
       illnesses, the lengthy course of HIV disease, its relatively high
       incidence among young and productive individuals, and management of drug
       toxicities have an enormous impact on total costs. Methodologic
       difficulties discussed include strategies for handling the effect of
       having a few high-cost cases and for summarizing effectiveness. The
       advantages and disadvantages of different measures of effectiveness,
       such as health status, quality of life, and utility in the setting of
       HIV disease, as well as the scaling of measures and approaches to
       handling death, are also addressed.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/*ECONOMICS/
       EPIDEMIOLOGY  Age Factors  Antiviral Agents/ADVERSE EFFECTS/ECONOMICS
       Cost-Benefit Analysis/*ECONOMICS  Disease Progression  Health Status
       Human  Quality of Life  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       Non-P.H.S.  Support, U.S. Gov't, P.H.S.  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

